货号:A162514
同义名:
NSC309132; 4-Deoxyuridine
Zebularine是一种DNA甲基化抑制剂,能够与DNA甲基转移酶形成共价复合物,同时抑制胞苷脱氨酶,Ki值为2 μM。Zebularine诱导大鼠骨髓间充质干细胞 (MSCs) 分化为心肌细胞。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | DNA Methyltransferase ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6-Thioguanine | ✔ | 98% | |||||||||||||||||
| Zebularine | ✔ | 98% | |||||||||||||||||
| Procainamide HCl | ✔ | 99% | |||||||||||||||||
| 5-Azacytidine | ✔ | 95% | |||||||||||||||||
| Decitabine | ✔ | 99% | |||||||||||||||||
| SGI-1027 |
++
DNMT3A, IC50: 7.5 μM DNMT1, IC50: 6 μM |
99%+ | |||||||||||||||||
| RG108 |
+++
DNA methyltransferase, IC50: 115 nM |
99%+ | |||||||||||||||||
| Guadecitabine sodium | ✔ | 98% | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | The DNA methyltransferase (DNMT) family are enzymes that can mediate the DNA methylation. Inhibiting the DNMTs have shown particular promise in reducing the formation of tumors[6]. Zebularine is a second-generation inhibitor of DNMT with IC50 value of 95 nM on DNMT1[7]. The TFK-1 and HuCCT1 cells were treated with zebularine from 100 - 1000 µM for 72 hours. The cell viability was significantly reduced in a dose dependent manner measured by WST assay. The protein expression level of DNMT1, DNMT3a, DNMT3b examined by western blotting assay was significantly inhibited for both cell lines at concentration of 400 µM and above[8]. BALB/c nude mice with tumor were treated with 10, 50 and 100 mg/kg zebularine via oral gavage in a solution of 0.45% saline every four days for 20 days. The tumor growth was reduced in a dose dependent manner and the cell death in the tumor mass via apoptosis was induced by the treatement of zebularine as measured by the TUNEL assay[9]. |
| 作用机制 | Zebularine could form tight covalent complexes between the DNMT proteins and zebularine-substitute DNA[10]. |
| Concentration | Treated Time | Description | References | |
| HaCaT cells | 1 μg/mL | 48 h | To investigate the effect of Zebularine on the proliferation and cytotoxicity of HaCaT cells. Results showed that Zebularine slightly stimulated proliferation at low concentrations (0.1 and 1.0 μg/mL) but inhibited proliferation at higher concentrations. | EBioMedicine. 2019 Aug;46:317-329. |
| 46BR.1N cells | 1 μg/mL | 48 h | To investigate the effect of Zebularine on the proliferation and cytotoxicity of 46BR.1N cells. Results showed that Zebularine slightly stimulated proliferation at low concentrations (0.1 and 1.0 μg/mL) but inhibited proliferation at higher concentrations. | EBioMedicine. 2019 Aug;46:317-329. |
| Arabidopsis thaliana cells | 20 µM | 10 days | Screening for mutants sensitive to Zebularine, revealing that SMC6B mutants are highly sensitive to Zebularine | Plant Cell. 2023 Apr 20;35(5):1532-1547. |
| Diabetic LEC | 1–20 µM | 24 h | Zebularine treatment significantly increased Wnt-5a levels and stimulated wound healing in a dose-dependent manner, with a 1.6-fold increase by 24 h. | Diabetologia. 2023 Oct;66(10):1943-1958. |
| HL60 cells | 50 or 100 µM | 96 h | To investigate the effect of Zebularine on HL60 cell differentiation, results showed that Zebularine significantly increased the expression of the CD11b differentiation marker. | Cells. 2020 Aug 29;9(9):1991. |
| Administration | Dosage | Frequency | Description | References | ||
| Mice | Unilateral ureteral obstruction model | Intraperitoneal injection | 225 mg/kg | Once daily for 3 or 7 days | Zebularine significantly attenuated renal tubulointerstitial fibrosis and inflammation induced by unilateral ureteral obstruction. | Int J Mol Sci. 2022 Nov 14;23(22):14045 |
| BALB/c mice | Oral cancer model | Oral | 1 mg/ml | Daily, starting from PID 4 | To evaluate the analgesic effect of Zebularine in an oral cancer model, results showed that Zebularine significantly reduced tumor growth and produced mechanical and thermal antinociception. | Clin Cancer Res. 2014 Sep 15;20(18):4882-4893 |
| Mice | Ear pinna injury model | Intraperitoneal injection | 1000 mg/kg | 7 injections over 10 days | To investigate the effect of Zebularine on ear pinna wound regeneration in mice. Results showed that Zebularine significantly promoted ear hole repair, with the mean hole area decreasing by 83.2 ± 9.4% in treated mice compared to 43.6 ± 15.4% in control mice. | EBioMedicine. 2019 Aug;46:317-329. |
| Mice | MMTV-PyMT transgenic mice | Drinking water | 5 mg/mL | Daily, for 48 days | Zebularine significantly delayed mammary tumor growth, and after 48 days of treatment, the tumors were predominantly necrotic, with a high apoptotic index observed by TUNEL assay as early as 13 days following treatment. | Mol Cancer Ther. 2012 Feb;11(2):370-82 |
| Mice | Experimental autoimmune uveitis (EAU) model | Intraperitoneal injection | 10 µg/g | Once daily for 7 consecutive days | To evaluate the effect of zebularine on intraocular inflammation in EAU mice, results showed that zebularine significantly alleviated intraocular inflammation and retinal tissue damage. | Front Immunol. 2019 Aug 16;10:1950 |
| Dose | Mice: 500 mg/kg[3] (i.p.); 100 mg/kg[4] (i.v.); 1000 mg/kg[4] (p.o.) Dog: 4 mg/kg, 8 mg/kg[5] (p.o.) | ||||||||||||||||||||||||||||||||
| Administration | i.p., i.v., p.o. | ||||||||||||||||||||||||||||||||
| Pharmacokinetics |
|
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
4.38mL 0.88mL 0.44mL |
21.91mL 4.38mL 2.19mL |
43.82mL 8.76mL 4.38mL |
|
| CAS号 | 3690-10-6 |
| 分子式 | C9H12N2O5 |
| 分子量 | 228.2 |
| SMILES Code | O=C1N=CC=CN1[C@H](O[C@@H]2CO)[C@H](O)[C@@H]2O |
| MDL No. | MFCD04973699 |
| 别名 | NSC309132; 4-Deoxyuridine; Pyrimidin-2-one beta-ribofuranoside; Pyrimidin-2-one ribonucleoside |
| 运输 | 蓝冰 |
| InChI Key | RPQZTTQVRYEKCR-WCTZXXKLSA-N |
| Pubchem ID | 100016 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, 2-8°C |
| 溶解方案 |
DMSO: 105 mg/mL(460.12 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO H2O: 50 mg/mL(219.1 mM),配合低频超声助溶 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1